tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KALV Stock Latest News

KalVista price target raised to $37 from $27 at H.C. Wainwright
The FlyKalVista price target raised to $37 from $27 at H.C. Wainwright
6d ago
KALV
KalVista price target raised to $29 from $28 at Citizens
PremiumThe Fly
KalVista price target raised to $29 from $28 at Citizens
6d ago
KALV
Strong Ekterly Launch and Latin America Expansion Underscore Buy Rating on KalVista
PremiumRatings
Strong Ekterly Launch and Latin America Expansion Underscore Buy Rating on KalVista
7d ago
KALV
KalVista Highlights Strong EKTERLY Launch and Global Uptake
PremiumCompany Announcements
KalVista Highlights Strong EKTERLY Launch and Global Uptake
7d ago
8K
KALV
KalVista price target raised to $32 from $28 at Needham
PremiumThe Fly
KalVista price target raised to $32 from $28 at Needham
9d ago
KALV
LQDA
KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
PremiumRatingsKalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
9d ago
KALV
KalVista says MHLW in Japan grants marketing, manufacturing approval for Ekterly
Premium
The Fly
KalVista says MHLW in Japan grants marketing, manufacturing approval for Ekterly
24d ago
KALV
Promising Launch of KalVista’s Ekterly Drives Buy Rating Amid Positive Market Dynamics
Premium
Ratings
Promising Launch of KalVista’s Ekterly Drives Buy Rating Amid Positive Market Dynamics
1M ago
KALV
Pharvaris price target raised to $50 from $44 at Oppenheimer
PremiumThe Fly
Pharvaris price target raised to $50 from $44 at Oppenheimer
1M ago
KALV
PHVS
KalVista Pharmaceuticals: Strategic Market Position and Strong Buy Recommendation
PremiumRatings
KalVista Pharmaceuticals: Strategic Market Position and Strong Buy Recommendation
1M ago
KALV
Positive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential
PremiumRatings
Positive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential
1M ago
KALV
KalVista Pharmaceuticals: Strong Market Position and Promising Future with Ekterly Leading the Way
PremiumRatings
KalVista Pharmaceuticals: Strong Market Position and Promising Future with Ekterly Leading the Way
1M ago
KALV
KalVista Pharmaceuticals, Inc. (KALV) Q2 Earnings Cheat Sheet
PremiumPre-EarningsKalVista Pharmaceuticals, Inc. (KALV) Q2 Earnings Cheat Sheet
1M ago
KALV
KalVista Pharmaceuticals Reports Strong Q3 Results
Premium
Company Announcements
KalVista Pharmaceuticals Reports Strong Q3 Results
2M ago
KALV
Optimistic Buy Rating for KalVista Pharmaceuticals Driven by Ekterly’s Strong Performance and Growth Potential
Premium
Ratings
Optimistic Buy Rating for KalVista Pharmaceuticals Driven by Ekterly’s Strong Performance and Growth Potential
2M ago
KALV
Positive Outlook for KalVista Pharmaceuticals: Buy Rating Affirmed Due to Strong Financial Performance and Market Demand for Ekterly
PremiumRatings
Positive Outlook for KalVista Pharmaceuticals: Buy Rating Affirmed Due to Strong Financial Performance and Market Demand for Ekterly
2M ago
KALV
KalVista price target lowered to $28 from $29 at Citizens JMP
PremiumThe Fly
KalVista price target lowered to $28 from $29 at Citizens JMP
2M ago
KALV
KalVista Pharmaceuticals: Strong Market Performance and Growth Potential Justify Buy Rating
PremiumRatings
KalVista Pharmaceuticals: Strong Market Performance and Growth Potential Justify Buy Rating
2M ago
KALV
KalVista reports Q3 EPS (92c) vs. (84c) last year
PremiumThe Fly
KalVista reports Q3 EPS (92c) vs. (84c) last year
2M ago
KALV
Buy Rating for KalVista Pharmaceuticals Driven by Strong Ekterly Uptake and Optimistic Revenue Projections
PremiumRatingsBuy Rating for KalVista Pharmaceuticals Driven by Strong Ekterly Uptake and Optimistic Revenue Projections
2M ago
KALV
KalVista’s Pediatric HAE Study: A Potential Game-Changer?
Premium
Company Announcements
KalVista’s Pediatric HAE Study: A Potential Game-Changer?
3M ago
KALV
KalVista’s Icatibant Study: A Potential Game-Changer for HAE Treatment?
Premium
Company Announcements
KalVista’s Icatibant Study: A Potential Game-Changer for HAE Treatment?
3M ago
KALV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >